Dermatology Diagnostic Developer, MELA Sciences, to Host Q4 Conference Call Monday, March 17, 2014 at 4:30 pm ET
March 06 2014 - 9:36AM
Business Wire
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®, an
FDA approved optical diagnostic device that assists dermatologists
in melanoma diagnosis, will release its fourth quarter and full
year 2013 results on Monday, March 17, 2014, after the market’s
close. MELA Sciences President and CEO, Rose Crane will host a
conference call that day at 4:30pm ET to review the results and
provide general business update.
To participate in the conference call,
please dial:
Domestic toll-free:
(877) 303-9205
International:
(760) 536-5226
Live Webcast & Replay:A live webcast will be
available at: www.melasciences.com/investors/homeIf you are
unable to participate during the live call and webcast, a replay
will be archived and available for approximately 90 days after the
call.
About MELA Sciences, Inc. www.melasciences.comMELA
Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The
flagship product is MelaFind®, an FDA, PMA and CE Mark approved,
non-invasive diagnostic tool to aid dermatologists in melanoma
evaluation and diagnosis. MelaFind® uses a variety of visible to
near-infrared light waves to evaluate skin lesions from the surface
to 2.5 mm beneath the skin. It provides images and data on the
relative disorganization of a lesion's cell structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA
is also exploring new potential uses for its core imaging
technology and algorithms.
Please follow us:
Twitter:
@MELASciencesIR or @MelaFind
Facebook:
www.facebook.com/MelaFind
StockTwits:
@MELASciencesIR
BoardVote:
MELA Sciences
MediaMELA Sciences, Inc.Diana Garcia Redruello,
212-518-4226dgarcia@melasciences.comorInvestorsCatalyst
GlobalToni Trigiani, David Collins,
212-924-9800mela@catalyst-ir.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024